<DOC>
	<DOCNO>NCT00090974</DOCNO>
	<brief_summary>RATIONALE : Quality-of-life assessment postmenopausal woman receive hormone therapy breast cancer may help determine effect treatment patient may improve quality life future breast cancer patient . PURPOSE : This clinical trial study quality life postmenopausal woman receive either exemestane anastrozole without celecoxib stage I , stage II , stage IIIA primary breast cancer .</brief_summary>
	<brief_title>Quality Life Postmenopausal Women Who Are Receiving Either Exemestane Anastrozole With Without Celecoxib Stage I , Stage II , Stage IIIA Primary Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare treatment-related symptom use Functional Assessment Cancer Therapy-Endocrine Symptoms ( FACT-ES ) questionnaire postmenopausal woman receptor-positive stage I , II , IIIA primary breast cancer undergo treatment exemestane v anastrozole without celecoxib protocol CAN-NCIC-MA27 . Secondary - Compare health-related quality life use FACT-ES questionnaire patient treat regimen . - Determine extent difference treatment-emergent symptom affect overall quality life patient treat regimen . OUTLINE : This multicenter , companion study . Patients receive treatment CAN-NCIC-MA27 . Health-related quality life treatment-related symptom assess use Functional Assessment Cancer Therapy-Endocrine Symptoms ( FACT-ES ) questionnaire baseline 3 , 6 , 12 , 24 month . PROJECTED ACCRUAL : A total 1,253 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer pT13 ; pNX , pN02 pN3* ; M0 NOTE : *Only sole basis classification presence 10 involved axillary lymph node Registered protocol CANNCICMA27 within past week Hormone receptor status : Estrogen receptor and/or progesterone receptorpositive immunohistochemistry tumor receptor content â‰¥ 10 fmol/mg protein At least 1 tumor must receptorpositive patient bilateral breast cancer PATIENT CHARACTERISTICS : Age Postmenopausal Performance status ECOG 02 Sex Female Menopausal status Postmenopausal Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Able read , understand , complete quality life questionnaires PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>